Liquid stable bovine virus vaccines
The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, in sucrose, arginine, and methionine. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
1. A liquid stable vaccine that comprises a live attenuated bovine virus, 20-40% (w/v) sucrose, 0.15 to 0.75 M arginine, and 0.025 to 0.3 M methionine; wherein the liquid stable vaccine has a pH of 6.0 to 8.0; and wherein the live attenuated bovine virus is selected from the group consisting of infectious bovine rhinotracheitis virus (IBR), parainfluenza type 3 virus (PI3), bovine respiratory syncytial virus (BRSV), and any combination thereof.
2. The liquid stable vaccine of claim 1 that further comprises a surfactant.
3. The liquid stable vaccine of claim 2 wherein the surfactant is polyoxyethylene-polyoxypropylene block copolymer.
4. The liquid stable vaccine of claim 1 that further comprises a chelator.
5. The liquid stable vaccine of claim 4 wherein the chelator is ethylenediaminetetraacetic acid (EDTA).
6. The liquid stable vaccine of claim 1 that further comprises an antioxidant.
7. The liquid stable vaccine of claim 6 wherein the antioxidant is selected from the group consisting of ascorbic acid, alpha-tocopherol, glutathione, and any combination thereof.
8. The liquid stable vaccine of claim 1 that further comprises a buffer.
9. The liquid stable vaccine of claim 8 wherein the buffer comprises 2.5 to 50 mM potassium phosphate.
10. The liquid stable vaccine of claim 9 , wherein the live attenuated bovine virus is a live attenuated IBR.
11. The liquid stable vaccine of claim 10 that further comprises a live attenuated BRSV.
12. A method of vaccinating a bovine comprising administering to the bovine the liquid stable vaccine of claim 1 .
13. A method of making a liquid stable vaccine that comprises combining a therapeutically effective amount of a live attenuated bovine virus with 20-40% (w/v) sucrose, 0.15 to 0.75 M arginine, and 0.025 to 0.3 M methionine; wherein the liquid stable vaccine has a pH of 6.0 to 8.0; and wherein the live attenuated bovine virus is selected from the group consisting of infectious bovine rhinotracheitis virus (IBR), parainfluenza type 3 virus (PI3), bovine respiratory syncytial virus (BRSV), and any combination thereof.
14. A liquid stable vaccine that comprises a live attenuated infectious bovine rhinotracheitis virus (IBR), 20-40% (w/v) sucrose, 0.15 to 0.75 M arginine, and 0.025 to 0.3 M methionine; wherein the liquid stable vaccine has a pH of 6.0 to 8.0.
15. The liquid stable vaccine of claim 14 that further comprises a live attenuated bovine BRSV.
16. The liquid stable vaccine of claim 15 that further comprises a live attenuated PI3.
17. The liquid stable vaccine of claim 14 that further comprises a live attenuated PI3.
18. The liquid stable vaccine of claim 1 , wherein the live attenuated bovine virus is a live attenuated PI3.
19. The liquid stable vaccine of claim 18 that further comprises a live attenuated BRSV.
20. The liquid stable vaccine of claim 1 , wherein the live attenuated bovine virus is a live attenuated BRSV.
21. The liquid stable vaccine of claim 11 that further comprises a live attenuated PI3.
22. A method of vaccinating a bovine against infectious bovine rhinotracheitis (IBR) virus, parainfluenza type 3 (PI3), and bovine respiratory syncytial virus (BRSV), comprising administering to the bovine the liquid stable vaccine of claim 16 .